Nucleic Acids Research, 1991, Vol. 19, No. 12 3359-3368
© 1991
MOLECULAR BIOLOGY |
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element
ISIS Pharmaceuticals 2280 Faraday Avenue, Carlsbad, CA 92008 1Southern Research Institute 2000 9th Avs S., Birmingham, AL 35255, USA
* To whom correspondence should be addressed
Received February 28, 1991. Revised May 16, 1991. Accepted May 16, 1991.
All human immunodeficiency virus mRNAs contain a sequence known as TAR (trans-activating responsive sequence). The TAR element forms a stable RNA stemloop structure which binds the HIV tat (trans-activator) protein and mediates increased viral gene expression. In principle, molecules which bind to the TAR RNA structure would inhibit trans-activation by perturbing the native RNA secondary structure. We have constructed a series of phosphodiester and phosphorothioate antisense oligonucleotides which specifically bind to the HIV TAR element. Specific binding to the TAR element was demonstrated in vitro with enzymatically synthesized TAR RNA. The TAR-directed phosphorothioates inhibited trans-activation in a sequence-dependent fashion in a cell culture model using an HIV LTR/human placental alkaline phosphatase gene fusion and tat protein supplied in trans. The molecules also inhibited HIV replication in both acute and chronically infected viral assays, but without sequence specificity. We have constructed a series of vectors consisting of the MMTV promoter and 5'-untranslated region of four different mRNAs, including the TAR region, to study the effect of TAR on gene expression in heterologous systems. The results suggest that, in the absence of the HIV LTR, the TAR element has a repressive effect on gene expression, which is relieved by tat.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Turner, A. A. Arzumanov, and M. J. Gait Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides Nucleic Acids Res., January 7, 2005; 33(1): 27 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Skripkin, J.-C. Paillart, R. Marquet, M. Blumenfeld, B. Ehresmann, and C. Ehresmann Mechanisms of Inhibition of in Vitro Dimerization of HIV Type I RNA by Sense and Antisense Oligonucleotides J. Biol. Chem., November 15, 1996; 271(46): 28812 - 28817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stein and Y. Cheng Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science, August 20, 1993; 261(5124): 1004 - 1012. [Abstract] [PDF]
|
|